In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 ...

TWiV reviews Michael Worobey's dissection of the early COVID-19 cases in Wuhan, and the discovery that herpesviruses assimilate cellular kinesin to produce motorized virus particles. Click arrow to playDownload TWiV 833 (77 MB .mp3, 128 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show notes at microbe.tv/twiv

TWiV reviews the vials labeled smallpox that were not, re-emergence of enterovirus D68 in Europe, efficacy of inactivated SARS-CoV-2 vaccine, and cellular correlates of protection for an oral influenza virus vaccine. Click arrow to playDownload TWiV 832 (77 MB .mp3, 128 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show notes at microbe.tv/twiv

In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals. Click arrow ...

TWiV explains that a recent report suggesting that the SARS-CoV-2 spike protein inhibits V(D)J recombination in vitrowould not impact immunity after infection or vaccination, and describes the isolation of remdesivir resistant mutants in cells in culture, and the emergence of amino acid changes in the spike protein identical to those in ...